15 Jan BlueWhale Bio
Peter Keller, CEO
April 28 | 5:30pm | Salone dei Cavalieri, Section 1
Philadelphia, PA
(Private)
BlueWhale Bio accelerates the adoption of cell-based therapies by modernizing cell manufacturing. The company is developing a portfolio of critical materials that enable higher-performing cell therapies to reach more patients faster and at lower cost. BlueWhale’s innovations stem from discoveries in cell activation by Dr. Carl June and Dr. Jim Riley at the University of Pennsylvania. Its Synecta™ platform uses cell-derived nanoparticles (CDNPs) that mimic the natural activation of immune cells, producing superior cell quality through a simplified, faster, and more scalable workflow. The first product, Synecta T1, mimics natural T-cell stimulation by delivering membrane-bound signals, cytokines, and adhesion molecules that enhance T-cell receptor engagement during CAR-T manufacturing.
